{"entity":{"id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","aka":[],"tldr":"A phase 3 trial of Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection in non-small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","summary":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC is a phase 3 interventional study registered as NCT06123754 by 3D Medicines (Sichuan) Co., Ltd., with 390 participants planned, started 2023-11-17 and due to reach its primary completion in 2027-12-30. Interventions recorded: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection and placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06123754","url":"https://clinicaltrials.gov/study/NCT06123754"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["envafolimab"],"companies":["3d-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06123754","phase":"3","setting":"A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer","sponsor":"3D Medicines (Sichuan) Co., Ltd.","started":"2023-11-17","startedType":"actual","enrolled":390,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06123754/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"}],"company":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/"}]}}